Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02161744 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Preliminary Efficacy of Adipose Derive Stem Cells for Patients With COPD
A Phase 1 study, sponsored by Arkansas Heart Hospital.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02161744 is a Phase 1 study that was terminated before completion, run by Arkansas Heart Hospital. The registered enrollment target is 9 participants.
The verdict
NCT02161744, a Phase 1 study, was terminated before completion, sponsored by Arkansas Heart Hospital.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is: 1.- to assess the safety and tolerability of autologous adipose derived stem cells (aADSC) administered intravenously in patients with chronic obstructive pulmonary disease, and 2.- to assess if this therapy results in less decrease of lung function parameters (FEV1, FEV1/FVC and 6 min walking distance) compared with a control baseline of 6 weeks. Patients will be followed up for 12 months after the therapy.
Interventions
- BIOLOGICAL ADSCs administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2013-10-10 |
| Est. Completion | 2018-10-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02161744
The ClinicalTrials.gov registry entry for NCT02161744 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arkansas Heart Hospital, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ADSCs administration is the first listed.
NCT02161744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02161744 about?
NCT02161744 is a clinical study titled "Safety, Tolerability and Preliminary Efficacy of Adipose Derive Stem Cells for Patients With COPD". The purpose of this study is: 1.- to assess the safety and tolerability of autologous adipose derived stem cells (aADSC) administered intravenously in patients with chronic obstructive pulmonary disease, and 2.- to assess if this therapy results in less decrease of lung function parameters (FEV1, FE...
What is the current status of trial NCT02161744?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2013-10-10. Estimated completion is 2018-10-29.
What interventions are being tested in trial NCT02161744?
The interventions under investigation include: ADSCs administration (BIOLOGICAL).
Who is sponsoring clinical trial NCT02161744?
This trial is sponsored by Arkansas Heart Hospital, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.